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Resumo: Esclerose Múltipla (EM) é uma doença neurológica inflamatória desmielinizante 
importante devido à sua incidência, cronicidade e maior prevalência em adultos jovens. No 
estudo inicial de uma doença desmielinizante do Sistema Nervoso Central existe a necessidade 
de encontrar biomarcadores que possam melhor discriminar a EM de outras patologias. 
Atualmente, apenas as bandas oligoclonais (BOC) são utilizadas. Esta revisão pretende, através 
de uma pesquisa na base de dados PubMed, examinar a literatura publicada nos últimos 5 
anos, sobre o papel dos biomarcadores no diagnóstico da esclerose múltipla. O uso de 
marcadores no líquido encéfalo-raquidiano, aumenta a especificidade e valor preditivo 
negativo, diminuindo os possíveis falsos positivos da, muito sensível, ressonância magnética. 
As BOC confirmaram o seu valor, apoiando o diagnóstico quando presentes e sugerindo a 
revisão do mesmo quando ausentes, mostrando contudo algumas limitações: variabilidade 
interpopulacional, laboratorial e metodológica, controvérsia sobre o uso do índice IgG, a 
interpretação de uma única BOC e a relação das BOC com a EM. Enquanto o vírus Epstein-Barr 
e os anticorpos antimielina falharam quando testados, as cadeias leves livres K demonstraram 
resultados promissores, especialmente, como todos os biomarcadores, quando combinadas 
com ressonância magnética. Na previsão de conversão do síndrome clínico isolado para EM, as 
BOC confirmaram o seu papel, enquanto CXC quimiocina motif 13 e a reação MRZ mostraram 
bons valores preditivos, e os marcadores de lesão axonal e anticorpos contra a mielina 
falharam. Além da deteção de anticorpos aquaporina-4 e a reação MRZ no líquido 
céfaloraquidiano a deteção de N-acetil aspartato no sangue mostraram bons resultados a 
distinguir EM de neuromielite ótica. Há uma procura para desenvolver métodos automatizados 
para estudar biomarcadores, e o desenvolvimento de técnicas proteómicas é promissor para a 
identificação de novos alvos moleculares para ensaios de diagnóstico e terapêutica. 
Concluindo, o principal contributo dos biomarcadores no diagóstico de EM, consiste no 
aumento de especificidade e valor preditivo. É necessário corrigir qualquer possível erro 
metodológico, tentando estandardizar ao máximo de modo a obter resultados mais 
consistentes. Apesar dos esforços na pesquisa de novos biomarcadores é necessário 
compreender melhor a EM de modo a encontrar um teste simplificado. 
Palavras-chave: Esclerose Múltipla, Síndrome clínico isolado, bandas oligoclonais, líquido encéfalo-
raquidiano, biomarcadores, diagnóstico. 
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Abstract 
Multiple Sclerosis (MS) is an important inflammatory demyelinative neurologic 
disease, due to its, incidence, chronicity and higher prevalence among young adults. In 
the initial  approach to a demyelinative disease of the Central Nervous System there is a 
urge for biomarkers to best discriminate MS from other diseases. Despite the broad 
range of biomarker studies, only oligoclonal bands (OCB) are used by routine in 
differential diagnosis. This review aims to access the published literature in the last 5 
years (trough a search in PubMed database), regarding the role of biomarkers in the 
diagnosis of MS. Regarding MS differential diagnosis, the use of cerebrospinal fluid 
markers (CSF) increases specificity and negative predictive, diminishing the possible 
false positives from the high sensible magnetic resonance imaging (MRI). OCB 
confirmed they value, supporting the MS diagnosis when present and suggesting 
revision of this, but some limitations appeared regarding inter-population, inter-
laboratories and inter-methods detection variability and there’s controversy concerning 
the current use of IgGindex, interpretation of a single weak OCB and the relation of 
OCB with MS. While Epstein Barr Virus (EBV) and anti-myelin antibodies failed when 
tested, Kappa free light chains (KFLC) performed in a promising way, specially, as all 
biomarkers, when combined with MRI. 
In this review, OCB confirmed they importance while C-X-C motif chemokine 
13 (CXCL13) and MRZ reaction showed good predictive values results while axonal 
damage markers and antibodies against myelin didn’t perform well, predicting clinically 
isolated syndrome (CIS) conversion to MS. Besides aquaporin-4 antibody detection and 
MRZ reaction in CSF, N-acetyl aspartate detection in serum showed good results 
distinguishing MS from neuromyelitis optica (NMO). There has been a struggle to 
develop standard easy automated methods to biomarker studying and the development 
of more sensitive proteomic techniques is very promising for the identification of new 
molecular targets for diagnostic assays and therapies preventing axonal damage.  
Concluding, biomarkers major contribute is in terms of Specificity and 
predictive value. Methodological standardization, correcting any possible error, is vital 
for a more consistent research. Despite the efforts in this field, an accurate simple test is 
only possible when the pathophysiology of MS is better understood.  
Keywords: Multiple Sclerosis, Clinically isolated syndrome, oligoclonal bands, 
cerebrospinal fluid, biomarker, diagnosis.
1. Introducion  
1.1 Historic note and state of art 
 Multiple Sclerosis (MS) is an important inflammatory demyelinative neurologic 
disease, due to its incidence, chronicity and tendency to affect young adults.(1) MS 
features a broad heterogeneity of clinical, histopathological and immunological 
phenotypes, which urges a more accurate defining of patients by biological markers that 
reflect the underlying disease process and allow the prediction of disease course and 
treatment response.(2, 3) Thus, serious efforts are made in the field of biomarkers to 
improve the diagnostic discrimination, to determine prognostic factors, and to identify 
markers to monitor the clinical course and response to disease-modifying therapies.(3) 
Starting with Charcot (1868) and his triad (nystagmus, intention tremor and 
scanning speech), the diagnostic criteria for  MS have evolved to reflect the 
breakthroughs in our understanding of the disease and the development of new 
diagnostic techniques, changing from purely clinical criteria to increasing dependency 
upon imaging of the central nervous system (CNS). Only in 1954 the first true 
diagnostic scheme appeared, published by Allison and Millar describing three 
categories: early, probable and possible disseminated sclerosis.(1) 
There was a need for reliable and reproducible diagnostic criteria in order to 
provide accurate epidemiological studies and therapeutic trials. A major step in that 
direction occurred in 1965, when Broman et al. outlined the principles that were the 
basis for following schemes.(4) They consisted of age of onset, the empiric significance 
of symptoms for an MS diagnosis, the multiplicity of lesions, the number of bouts, and 
the familial “recurrence” of MS. The results of the newly described electrophoretic 
examination of cerebrospinal fluid (CSF) protein, the precursor of oligoclonal bands 
(OCB), were also introduced. Additionally, all other possible diagnoses were to be 
considered and, if possible, excluded. For the first time was stated the twin principles of 
dissemination in time and in space, that to this day remain the fundamental criteria for 
the diagnosis of MS.(4) The further need for accurate diagnosis criteria, lead to the 
formation of an expert panel and elaboration of the Schumacher et al. criteria, used 
worldwide.(5) 
A adaptation of the Schumacher criteria emerged from a worldwide 
investigation by Bauer that was the first to include CSF OCB.(1) 
One problem with the diverse published diagnostic classifications is their 
different terminology and the subjective judgment required. This problem cannot be 
completely overcome but can be diminished in the absence of a totally specific 
laboratory test for MS by adding to the clinical evaluation, the results of laboratory, 
neuroimaging, and neurophysiological procedures.(1) 
New criteria (Poser et al. criteria) were published in 1983 and consisted of two 
main groups, definite and probable, each with two subgroups, clinical and laboratory 
supported.(6) Furthermore, for the first time definitions of the terms used were agreed. 
An attack/exacerbation could consist of symptoms alone lasting at least 24 h. The term 
“paraclinical” evidence was introduced to comprise the results of evoked response 
studies and neuroimaging. One problem of this scheme was the failure to incorporate 
consideration of primary progressive MS (PPMS). These criteria promptly replaced 
previous ones for epidemiological studies and selection of patients for therapeutic drug 
trials as well in clinical practice.(6) The 2001 McDonald et al. diagnostic criteria 
resulted in two major changes: MRI criteria were incorporated into the scheme, and 
long-needed guidelines for the diagnosis of primary progressive MS were defined.(7) 
 OCBs, best detected by isoelectric focusing followed by immunoblotting, is the 
only biomarker present on the latest 2005 Revisions to the Mcdonald Criteria for MS. 
According to these criteria, “elevated immunoglobulin G (IgG) index or ≥2 OCB in 
CSF can be important to support the inflammatory demyelinating nature of the 
underlying condition, to evaluate differential diagnosis and to predict clinically 
definitive MS”.(8) 
 
1.2 Biomarkers 
Biomarkers are measurable indicators of a physiologic or pathologic process or 
the effects of a therapeutic intervention. An ideal biomarker would thus be binary, 
missing in a healthy individual, only present in the disease state and increasing with the 
severity of the latter.(9) Characteristics that define biomarkers are usually limited to 
detection of specific proteins in body fluids that become altered as a consequence of a 
biologic or pathologic process.(2, 9, 10) 
 Since MS lesions are rarely biopsied, CSF analysis remains an important and 
practical tool to understand the underlying immunopathogenesis in patients presenting 
with a first demyelinating event or with early MS. It is possible to detect and measure a 
various number of particles by several techniques.(3, 11) Differential therapeutic 
approaches requires the development of biological markers that objectively: 1)reflect 
the targeted immunopathological process, 2)select patients in which the pathogenic 
process predominates, 3)show responses to treatment, 4)provide a simple and economic 
monitoring tool in clinical trials and routine patient management.(2) In a complex 
disease like MS with different pathogenetic mechanisms, a single biomarker is likely to 
reflect only one of many ongoing pathogenic processes. Thus, the stratification of 
patients might only be possible by using a defined set of biomarkers. Each biomarker 
will have to be validated across diverse patient cohorts in prospective, multicentre 
studies for the following goals: 
1) clinical relevance: the biomarker has the capability to reflect the change of a 
pathologic process and/or therapeutic intervention in a relatively short period; 
2) sensitivity: the ability to be measured with adequate precision and sufficient 
magnitude of change to reflect a meaningful change in important clinical endpoints; 
3) specificity: the power to identify patients by the occurrence of pathologic 
processes or the response to an intervention in terms of changes in a clinical endpoint; 
4) probability of false positive or false negatives: defined by the situations in 
which an estimated change of the biomarker is not reflected by the respective change in 
clinical endpoint; 
5) accuracy, precision, reproducibility and variability of the laboratory assay or 
test measurement of the biomarker.(2, 9) 
Some challenges to biomarker discovery and validation are: highly variable 
clinical course, heterogeneous mechanisms of disease, nonspecificity of disease 
markers, intra- and inter-individual variability in markers, variable responses to 
treatment, diagnosis of exclusion without “gold standard”, frequent subclinical disease 
activity, heterogeneous treatments with diverse mechanism of action.(12) 
The latest promise in biomarker discovery is the proteomic studies, which 
revealed a broad range of new possible biomarkers for MS. The discovery of new 
biomarkers would be crucial for accurate and earlier diagnosis.(3) 
 
1.3 Objective 
 The aim of this review is to assess the literature published in the last 5 years 
concerning the role of biomarkers in the diagnosis of MS and conversion of CIS to MS. 
The biomarkers concerning the MS evolution were excluded. 
 
2. Material and Methods 
 The bibliography used for this article was obtained on 15/11/2011 by a double 
research in the pubmed database. The first was made with the following query: 
(("cerebrospinal fluid" [Subheading]) AND ( "Multiple Sclerosis/cerebrospinal 
fluid"[Mesh] OR "Multiple Sclerosis/diagnosis"[Mesh] )) AND ( "Biological 
Markers/analysis"[Mesh] OR "Biological Markers/cerebrospinal fluid"[Mesh] OR 
"Biological Markers/diagnostic use"[Mesh] ), and the limits used were language 
(Portuguese, Spanish and English) and publication date (<5 years).  After reading the 
abstract and/or full article, 68 articles were selected from the 158 that resulted from the 
search. A second query (“multiple sclerosis AND diagnosis AND biomarkers”) without 
Mesh terms was used, with the same limits for language and with publication data 
limited to 6 months. 13 were selected from the 62 obtained and most of them were 
included in the previous research. From all the articles, only 4 of them couldn’t be 
acquired.  
 The bibliography of the studies above and additional literature considered 
relevant, was included in this review. Microsoft word from Microsoft office 2007, 
EndNote X5 and My NCBI were the tools used.  
 
3. Results and discussion    
3.1 MS diagnosis 
3.1.1 Role of OCB in MS diagnosis 
While MRI is now very sensitive, specificity is a problem. The MRI lesions are 
compatible with many pathophysiological mechanisms and thus different diseases, 
creating “false positives”.(13) MRI criteria for MS show limitations in equivocal MS 
cases. Therefore, it is imperative that other investigative procedures, such as CSF 
examinations, are established for MS diagnosis.(14) 
The major diagnostic contribution of OCB was in terms of Specificity and 
negative predictive value. Improved specificity is vital in differential diagnosis to rule 
out non-MS cases. Moreover the combination of MRI and CSF analysis proved to be 
more accurate than MRI alone.(15) The only marker used in the diagnostic procedure of 
MS is the qualitative and quantitative assessment of immunoglobulin G in CSF.(2, 12, 
16) Using optimized, standardized methodology, preferentially protein separation by 
isoelectric focusing (IEF) followed by immunoblotting, more than 95% of patients with 
MS have CSF OCB not detectable in serum, thereby providing powerful evidence for 
the diagnosis of MS. Because of the high sensitivity of CSF OB in MS as well as its 
high specificity in the appropriate clinical setting, examination of CSF for OB of IgG 
class can be strongly recommended to obtain support for the diagnosis of MS.(17) 
The IgG index equal to CSF/serum IgG:CSF/serum albumin is elevated in about 
70% of MS patients, but infrequently in CSF OB-negative MS. Because of lower 
diagnostic sensitivity, IgG index cannot be recommended as surrogate of CSF OB in the 
diagnosis of MS but, when elevated, as additional evidence for an augmented B-cell 
response within the CNS compatible with MS.(17, 18) 
A drawback with determination of the IgG index is that it may become falsely 
elevated in patients with moderate severe blood–CSF barrier damage. Detection of a 
moderately–strongly elevated CSF/serum albumin ratio should lead to reevaluation of 
an MS diagnosis. Still, the IgG index is more or less obtained for free in the context of 
practically every routine CSF examination.(17) 
Although the clinical picture as well as findings from magnetic resonance 
imaging of the brain and spinal cord is essential for an MS diagnosis, this should be 
reevaluated in CSF OB-negative patients, remembering the possible diseases imitating 
MS. Conversely, OCB are not specific and are found less frequently in other conditions 
that can clinically mimic MS, though usually OCB are only transient in these 
conditions, whereas they are present continuously in MS patients, regardless of disease 
activity or therapy, indicating a stable humoral immune response in CNS of MS 
patients.(2, 17, 19) Consequently, a positive laboratory test for OCBs has a high 
negative predictive value and a low positive predictive value, making it a sensitive 
screening tool but not a diagnostic one.(16) 
The significance of IgG migrating as one sharp (rare finding), monoclonal band 
in CSF while not detectable in corresponding serum is debated. If the IgG index is 
simultaneously elevated, then there is evidence for a local B-cell response, and this 
should be reported. Usually, however, the IgG index is normal. The monoclonal CSF 
IgG band may reflect a technical problem, and the examination for CSF OCB should be 
repeatedly performed on the same CSF and serum specimens. The significance of a 
single band in CSF remains unclear.(14, 17, 20) 
There are trans-ethnic and/or trans-population differences in OCB sensitivity in 
MS. Lower frequencies of CSF OCB have been reported from Asian and Southern 
countries: China (63.3%), Italy (73.2%), Turkey (85.7%) and Brazil (54.4%).(17, 21-
25) Different methods adopted for CSF OB detection, various disease sub-types, diverse 
genetic background, methodology or patient selection issues, can play a role in this 
differences.(17, 21, 22) Due to these differences, OCB are of less diagnostic value for 
MS in these areas (there was no significant difference between MS and other 
inflammatory neurological diseases in a Chinese study).(21) 
Different methods adopted for CSF detection can play a significant role in this 
matter. Despite the awareness of the advantages inherent to IEF + immunoblotting, 
several laboratories do not this method.(26, 27) It was argued that OCB detection 
usefulness is limited by high inter-laboratory variability.(13) A Spanish study 
demonstrated a high inter-laboratory reproducibility in high sensitivity techniques like 
IEF, while an Italian group identified an unacceptable large inter-laboratory variation 
not only in OCB numbering, but also in qualitative reporting of the OCB pattern and in 
differentiating OCB+ from OCB-.(23, 28) Nevertheless, results of CSF OCB testing 
should be considered in the context of the method used.(17, 28, 29) Recently OCB have 
been detected in the tears of patients with CIS with 100% specificity.(30)  
External quality control schemes are fundamental steps in standardization 
processes, particularly in the field of IEF, the recommended technique for OCB 
detection, because many IEF steps may be difficult to standardize and new centers lack 
specialized sections for CSF analysis. Misinterpretation of art factual bands, insufficient 
IEF skills or poor blotting and staining skills contribute to the inter-laboratory 
variability. Educational support and external quality control schemes, scientific 
associations involved in CSF analysis play essential roles in promoting quality.(29) 
A various number of studies comparing OCB positive MS patients with OCB 
negative, sometimes with contradictories results, regarding the OCB pattern, the 
fulfillment of MRI criteria, location of the lesions, disease course, CSF pattern 
demonstrated once more the heterogeneity of MS.(10, 31-33) Even the correlation 
between both parameters of intra-thecal synthesis is not yet clear.(34) 
In a patient where CSF OCB are expected but not detectable, the pair of 
CSF+serum might be re-examined, but this only very rarely leads to a different result. It 
is recommended that a complete routine CSF examination including test for IgG OCB 
with appropriate methodology is done before a MS patient is included in clinical trials 
with e.g. disease modulating drugs. The intent was that the Criteria could “be used by 
the practicing neurologist to better and more reliably diagnose MS, balancing earlier 
diagnosis with the need to avoid false-positive diagnosis”.(17) 
The diagnosis of PPMS is particularly difficult. The single large study referred 
to in the 2005 Revisions consists of 943 patients with a diagnosis of PPMS based on 
clinical, MRI and evoked potential data. “Supportive CSF findings” were obtained in 
about 80% of the patients, while the remaining 20% were ineligible because they did 
not fulfill the supportive CSF findings.(35) These consisted of CSF OCB, elevated IgG 
index or elevated IgG synthesis rate. The sensitivity of these variables differs 
significantly in the context of a diagnosis of MS (95%, 70%, and 70%, respectively if 
optimal tests are performed). Unfortunately, the three variables are equalized in the 
study.(35) This is not noticed in the 2005 Revisions. Further, the study gives no 
information regarding the procedures used for protein separation. A well-performed 
study published in 2004, showed that 58 of 60 patients with PPMS (97%) have IgG OB 
in CSF when examined by IEF+immunoblotting.(36) By adopting the 2005 Revisions, 
there could be a risk that patients not suffering from MS might be included, thereby 
jeopardizing the outcome of the trial.(17) 
Other OCB isotypes, like IgA and IgM appear to be of limited additional value 
in the diagnosis of MS.(16) IgA presence in MS is uncommon, suggesting other 
diagnosis.(37, 38) IgM OCB are identified up to 60% of MS patients (especially in 
childhood MS) and are more common in early phases of MS, being useful to select 
patients to receive early treatment, because may influence disease prognosis.(16, 39) 
Fifty years after their discovery, the OCB therefore continue to puzzle neuro-
immunologists.(19) It is highly recommended that the diagnostic MS criteria are further 
revised to incorporate the minimum of CSF tests recommended for use in order to 
support a diagnosis of MS and reduce the likelihood of another disease that mimics MS. 
Many questions regarding CSF OCB remain to be solved. Some of them are minor like 
the significance of a monoclonal band in CSF, the optimal way to proceed with CSF 
examinations in a patient who according to clinical and MRI criteria has MS but has no 
CSF OCB, the diagnostic role of detection of other Immunoglobulins or free light 
chains migrating as OCB in CSF, improved and simplified methods for detection etc. 
Some remaining questions are major like elucidating the role of CSF OCB in the 
pathogenesis of MS.(2, 17) 
 
3.1.2 Additional markers. 
Despite the numerous studies, there has been no definite association of OCB 
with a specific antigen in patients with MS and it is clear that the intra-thecal antibody 
synthesis is directed against diverse antigens. An association of these antibodies with 
the cause of MS is still missing.(2) Epstein-Bar virus (EBV) infection has been 
suspected as an initial trigger of autoimmunity in MS and, thus, evidence of EBV 
infection could have relevance for MS diagnosis.(10) 
A number of studies have shown that almost 100% of MS patients have evidence 
of prior EBV infection, whereas approximately 90% of healthy adults also have 
evidence of EBV infection.(40) Therefore, the presence of EBV antibodies is not 
considered to be diagnostic relevant. Furthermore, CSF reactivity to EBV antigens in 
MS compared with healthy controls has not yielded any specific associations.(41) 
Current investigations are focused on determining whether MS patients have 
antibodies to unique determinants of EBV, or if viral-clearance responses to EBV 
infection in MS patients are abnormal.(42) If these investigations are fruitful, they could 
have application as diagnostic markers.(10) 
Additionally, Bartos et al. (2007) reported no difference in antibodies against 
light neurofilaments in all sub-types of MS and other diseases.(43) 
 Nogo-A, an inhibitor of axonal regeneration, is a perfect example of the 
inconsistent and contradictory data gathered in this review. Jurewicz et al. (2007) 
reported that CSF Nogo-A may be specific (100%) for MS and its presence may predict 
failure of axonal regeneration within the CNS. Nogo-A was found in CSF of 96%  of 
MS patients and wasn’t present in meningo-encephalomyelitis, control subjects wither 
neurologic, and autoimmune diseases.(44) These findings lacked confirmation by 
William et al. (2008) with the same methodology.(45) Correspondence between authors, 
showed high discordance in this subject.  
Numerous studies have demonstrated elevated kappa free light chains (KFCLs) 
in CSF of MS patients. However, so far only small cohorts have been examined, and 
generally only through qualitative KFLCs analysis. Determining a single quantitative 
diagnostic FLC parameter (KFLC index) by nephelometry (highly automated) and IEF, 
Presslauer et al. (2008) showed higher sensitivity (96% vs 91%) but lower specificity 
(86% vs 92%) compared with OCB, but was far more accurate than IgG index. 
Additionally, there was no correlation between MS type, EDSS score, disease duration, 
or number/localization of MRI lesions and the value of KFLC or KFLC index.(14) 
The combined use of three FLC indices  accounting for monomeric FLC –k level 
and k/λ ratio values in the CSF and serum was found to be of promising diagnostic 
importance for differentiation of MS from other non-MS neurological diseases 
(specificity 93%, sensitivity 100% vs OCB 76% and 87% in the same cohort).(46) In 
contrast to the OCB test, where the result is interpreted as “positive”, “negative” or 
“trace”, this method provides quantitative evaluation of relative amounts of FLCs, as a 
measure of the severity of intrathecal immunoglobulin synthesis. This procedure for 
FLC analysis can serve as a basis of a new diagnostic test for MS. The described 
method is inexpensive, it requires no special requirement, and may be applied in clinical 
laboratories.(46) This procedure also allows preparation of samples in a dry state, that is 
helpful for prolonged storage and transportation of CSF and serum samples prior to 
their analysis.(46) 
As it is measured by automated, routinely available laboratory methods, KFLC 
quantification can provide a rapid and reproducible indication of intrathecal 
immunological processes supporting current MS diagnostic criteria.(14) These results 
strongly suggest that the KFLC index should be part of the routine MS diagnostic 
algorithm.(14, 46) Additional LFLC index determination can support the exclusion of 
alternative diagnoses. Alternative diagnoses should be considered if these are associated 
with concurrent significant elevation of LFLC levels.(14) 
Elevated CSF anti-MBP antibodies correlate well with acute myelin damage in 
the CNS, but are not specific to MS. Reproducible quantification of MBP has been 
difficult since immunoassays are not standardized and not commercially available.(3) 
CSF MBP has lacked specificity in most studies. The test was recently re-
evaluated by Tian et al. (2009) who reported a diagnostic sensitivity of 83.7% and 
specificity of 78.3%. These results need to be confirmed in further studies.(16, 47) 
Preliminary studies, approaching Gelsolin, leukemia inhibitory factor and 7-
ketocholesterol, showed good result, needing further evaluation.(48-50) 
In table 1, are displayed other biomarkers revised in this search. 
 
 
3.1.3 Conversion of Clinically Isolated Syndrome to Clinically Definitive Multiple 
Sclerosis 
In a significant percentage of patients who later develop MS, the disease initially 
presents with an acute or sub-acute episode of neurological symptoms due to a single 
demyelinating lesion, known as clinically isolated syndrome (CIS). Predict the risk of 
future events, confirming the MS diagnosis is crucial to begin an important early 
treatment. In the last few years, the main focus has been on diagnostic sensitivity in 
order to early detect the patients in need for early therapeutics, resulting therefore in 
possible over diagnoses.(51) In this context, the most relevant statistical parameters to 
predict conversion from CIS to MS are positive predictive value (PPV) and negative 
predictive value (NPV).(51) MRI is the main exam used to this prediction but there is 
an ongoing search for accurate biomarkers for this conversion.(52, 53) 
Tintoré et al. (2008) showed that detection of OCB in CSF approximately 
doubles the risk of having a second attack, autonomously of MRI, but does not seem to 
influence the development of disability.(54) This higher risk is more significant when 
MRI is normal or when there is not MRI criteria for dissemination in space (DIS) (4% 
of patients with normal MRI and negative OCB converted and 23% of those with 
normal MRI and positive OCB converted).(54) 
The association of OCB to MRI maximizes the risk; therefore they can be used 
together to better predict conversion to CDMS. OCB associated with number of 
Barkhof criteria and number of lesions but the absence of OCB should suggest 
extending the diagnosis workup.(15, 17) 
Similar results were found by other displayed on table 2.(15, 55-58) 
Additionally, two of these studies suggested that patients with OCB converts faster to 
CDMS (55, 57), especially when IgM is associated.(55) 
Brettsschneider et al. (2010) in a prospective pilot study with 91 patients and 2 
years of follow-up, showed that the presence of C-X-C motif chemokine 13 (CXCL13) 
in CSF has a better PPV (70%, augmented to 80% with Barkhof criteria) than OCB, 
Measles, Rubella and Varicella zoster reaction (MRZR, intra-thecal synthesis of specific 
antiviral IgG antibodies that supports the diagnosis) or Barkhof criteria.(59) 
A large clinical case-control cohort, including the whole spectrum of MS forms, 
as well as large numbers of inflammatory and non-inflammatory subjects with other 
neurologic diseases confirmed the potential role of CXCL13 as a MS disease activity 
marker. CXCL13 correlated with relapse rate, Expanded Disability Status Scale 
(EDSS), number of lesion on MRI and response to treatment.(60) However, this 
biomarker is not a disease-specific biomarker, but showed a close relationship with 
OCB and CSF cell counts.(59-61) 
Regarding antibodies against myelin, myelin oligodendrocyte glycoprotein 
(MOG), and myelin basic protein (MBP), discordant unexplained results have 
appeared.(62) Correlation ranged from highly significant (63), significant (64, 65), to 
not significant at all (62, 66). It is important to note that these controversial results were 
obtained with the same type of analysis of antimyelin antibodies, immunoblotting. 
Thus, these different results may primarily reflect differences in study cohorts rather 
than methodological problems.(2) Currently there is no proven value in the diagnostic 
and prognostic utility of CSF anti-myelin antibodies in patients with CIS.(16) 
CSF of patients with MS is characterized by a polyspecific, intrathecal B-cell 
response with a prominent antibody production against neurotropic viruses like measles, 
rubella and varicella zoster.(51) A prospective study with 89 CIS patients comparing 
MRZR with OCB and MRI lesion load showed that MRZR was significantly more 
frequent in CIS that developed MS during follow-up. Their data showed MRZR to have 
a high PPV.  MRZ score, produced according to the different prognostic relevance of 
the three antibody included in MRZR, had the best single PPV (79%), augmented when 
added to MRI (≥2 lesions, 91%).(51) 
An important drawback of MRZR is that there’s no workable combined assay to 
determine these antibodies. Therefore, another study from the same authors, following 
121 individuals for 2 years values more CXCL13 determination (PPV of 70%).(59) 
Axonal damage markers (tau and NfHSMI35) were measured by Brettschneider 
et al. (2006) in order to access their power to predict conversion from CIS to MS. CSF 
tau and NfHSMI35 were significantly elevated in CIS compared to controls, and 
correlated with disease activity.(67) The sensitivity predicting the conversion from CIS 
to MS was higher for the combination of CSF markers (either tau or NfHSMI35 
elevated) than for MRI (40 versus 34%), but could be further increased to 60% if CSF 
and MRI criteria were combined. Similarly, the combination of tau and NfHSMI35 
showed higher specificity (94%) than MRI (82%). Tau and NfHSMI35, according to 
this study, are valuable biomarkers for axonal damage in the CIS patients.(67) 
Other molecules showed results that need further evaluation: increased CSF 
cystatin C (in contrast with former studies), dissociation 14-3-3/tau protein in CSF, 
blood and CSF white blood cell count and neurofilament light.(68-71) 
In other hand, IgM and human leukocyte antigen G failed to be relevant in the 
evaluation of CIS.(72, 73) 
 
3.1.4 Multiple Sclerosis vs Neuromyelitis optica (NMO) 
An example of success in researching biomarkers for differential diagnosis of 
MS is the aquaporin-4 antibody. Recently, highly specific serum IgG antibodies were 
detected by immunofluorescence staining of mouse brain tissue in a majority (73%) of 
patients with definite NMO and in 46% of patients at high risk for NMO.(74) NMO-IgG 
had 91% specificity for NMO and were suggested to be a useful diagnostic biomarker in 
patients with their first episode of myelitis.(75, 76) Most recently a number of 
confirmatory studies from different laboratories using diverse assays and different 
cohorts of patients were published.(77-80) 
A positive MRZR, defined by a combination of  at least two antibody indices 
was found in 37/42 MS patients, while only in 1/20 NMO patients by Jarius et al. 
(2008) allowing the differentiation between MS and NMO.(81) 
Tortorella et al. (2011) demonstrated that MS patients show higher serum and 
CSF N-acetyl aspartate (NAA) levels than NMO patients, and higher serum NAA levels 
than healthy controls. High serum NAA values, exceeding the 95
th
 percentile of serum 
NAA value in healthy controls, were found in all MS patients and in none with NMO. 
No differences in serum NAA levels were found between NMO and healthy 
controls.(82) Therefore, serum and CSF NAA may be valuable in the diagnostic workup 
to differentiate MS from NMO.(82) 
 
3.1.5 Proteomics  
Multiple proteomic preliminary studies carried out in the past few years have 
revealed potential biomarkers candidates that may not otherwise have been discovered 
through function-based approaches.(10, 53, 83-88) For most of these candidate proteins, 
the pathophysiological relevance in MS remains to be clarified. Generally the disease 
specificity of these proteins is rather low, possibly due to common pathological 
mechanisms underlying different diseases.(53, 89) 
A problem of CSF proteome analysis is that high-abundance proteins, such as 
albumin and immunoglobulin, may overlay brain-specific low-abundance CSF proteins 
in the electrophoresis. Therefore, CSF has to be pre-processed to extract those extra-
proteins, possibly resulting in wasting proteins that are bounded do albumin.(53, 85) 
The advantages of mass spectrometry-based protein quantification are precision, 
sensitivity, throughput and convenience.(83) An important aspect in future CSF 
proteome studies is the standardization of sampling protocols, experimental design and 
data analysis, in order to reach consensus.(53) 
Further studies are needed to better characterize the correlation of these new 
candidate markers with MS.(88-90) 
 
4. Conclusion 
Diagnosis of MS is currently based on clinical presentation, MRI findings, and 
CSF examination (OCB and IgG index) and requires the exclusion of alternative 
diagnosis.(45) CSF is especially important in not making a diagnosis of MS; that is, in 
excluding other conditions that mimic MS and as a predictor of conversion to CDMS. 
As long as we do not know what causes MS we will not have a simple diagnostic test 
.(91) To understand the relation of marker concentrations in body fluids and 
neuropathological processes, the underlying process need further investigation.(92) 
With increasing sensitivity and resolution of analytical methods, the demands of 
rigorous control of sample handling and storage also increase.(93) Often, early studies 
show great potential, but subsequent reports on the same marker yield inconsistent or 
even contradictory results. The reasons for this are mainly methodological although the 
heterogeneity and the lack of solid knowledge about MS also contribute.(10, 12, 65, 72, 
94, 95) 
The use of OCB has some limitations and in result of MS heterogeneity, one 
marker possibly isn’t enough. In this respect, development of novel laboratory 
techniques and search for new reliable MS-specific markers remains of considerable 
diagnostic importance for MS.(46, 96) 
Other than OCB, MRZR and CXCL13 appeared like valuable markers for 
conversion of CIS to MS, and anti-myelin antibodies the opposite. Predicting 
conversion from CIS to MS can be improved combining MRI with CSF markers, but 
MRI remains as the major prognostic factor.(16, 54, 59, 67) 
 CSF OCB utility was demonstrated in diagnosing and predicting MS, with the 
awareness of the frequency variability in the different communities. When present, is a 
strong support for MS but the diagnosis should be reviewed in it absence.(21, 33) The 
equivalent use of IgG index comparing with OCB is inadequate according with some 
authors.(17) 
 Quantitative KFCL’s presented as a helpful marker for MS diagnosis, and 
should be further investigated.(46) 
 Besides aquaporin-4 antibody, the presence of NAA in the serum can be 
important to distinguish MS from neuromyelitis.(82) 
Even though OCB provide important information regarding MS diagnosis, there 
are currently no CSF biomarkers that can reliably and definitively diagnose MS at the 
time of initial symptoms.(10) The development of more sensitive proteomic techniques 
is very promising for the identification of new molecular targets for diagnostic assays 
and therapies preventing axonal damage.(92) 
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Table 2. Association between OCB and/or imaging and conversion from CIS to 
CDMS 
 
 
N 
Follow-
up 
(years) 
Sensibility Specificity PPV NPV RR1 RR2 
Tintoré et al. 
(2008) 
415 4.2   83 48 50 84 1.7 8.9 
Jai Perumal 
et al.(2007) 
58 5.2 100 61 53.1 100 53 - 
Isabel Boscá 
et al.(2010) 
192 6.2   95 60 78 88 9.4 
39.2
# 
Juan Rojas 
et al.(2010) 
40 5 87 60 56 88 5 9 
Valentina 
Zipoli et 
al.(2009) 
90 3.8 76 37 60 56 1.4 - 
Luisa Villar 
et al.(2011) 
* 
58 6 94 96 97 91 - - 
Table2. OCB: oligoclonal bands; CIS: Clinically isolated syndrome; CDMS: Clinically definitive 
Multiple Sclerosis; *:All values concern OCB+2 MRI lesions. #:This value concerns the 
combination of OCB and IgM. N: number of subjects in study; PPV: positive predictive value; 
NPV: negative predictive value; RR1: OCB relative risk; RR2: OCB combined with imaging 
relative risk.  
 
Table 1. CSF biomarkers valuable or not for the diagnosis of MS 
Not Valuable Valuable 
12,5 kDa Cystatin C (93) Gelsolin (48) 
BAAF (97) Leukemia inhibitory factor (49) 
Annexin-1 (98) 7- ketocholesterol(50) 
Anti-tubulin (99) 
ATP metabolites (100) 
Neurospecific enolase (92) 
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Types of article
Original Research Articles
Full length research papers will not normally be more than 3500 words in length from the Inotrduction
through the Discussion section and will preferably be shorter. Submission of a paper to Multiple
Sclerosis and Related Disorders will be held to imply that it represents original research not previously
published (except in the form of an abstract or preliminary report), that it is not being considered for
publication elsewhere, and that if accepted by Multiple Sclerosis and Related Disorders it will not be
published elsewhere in the same form in any language without the consent of the Publisher. Major
papers of topical content will be given priority in publication.
Book Reviews
These are normally submitted by the Book Review Editors, but they welcome suggestions of books
for review.
Case Reports
Case reports should detail the clinical, laboratory and neuroimaging features of informative patients.
Informative patients should provide insights that inform on genetic contributions to disease, rare
clinical manifestations, novel laboratory or imaging features, or highlight important concepts in the
differential of MS and related disorders. Case reports should be approximately 1200 words, and should
have no more than five key references
Comment
Comments should focus on specific issues relevant to MS and related disorders, or should discuss
recent publications. Comments should be less than 800 words and should reference the article(s)
upon which the commentary is based.
Clinical Trial papers
Manuscripts detailing the results of clinical trials in MS and related disorders are encourage. The trial
methodology should account for all screened participants, and analyses should observe an intention-
to -treat model where appropriate. All sources of funding for the study must be disclosed, and the
involvement of the study sponsor must be detailed. Clinical trial manuscripts should be a maximum
of 3500 words.
Editorials
The Editors welcome suggestions for editorials which give personal and topical views on subjects
within the Journal's area of interest. They should not normally exceed 1500 words in total, including
references.
Letters to the Editors
These normally refer to articles previously published in the Journal. The Editors are also willing to
consider letters on subjects of direct relevance to the Journal's interest. Letters should not exceed
1000 words in total and, where appropriate, must begin with the reference to the published article
about which the author is commenting. Research letters should be submitted as 'letter to the Editors'
Review Articles
Review papers are normally 4000-5000 words in total. Authors are advised to consult one of the
Editors with an outline before submitting a review.
Contact details for submission
Authors may send queries concerning the submission process, manuscript status, or journal
procedures to the Editorial Office at:
MSARD, Editorial Office, ELSEVIER.
E-mail: msard@elsevier.com
BEFORE YOU BEGIN
Ethics in publishing
For information on Ethics in publishing and Ethical guidelines for journal publication see
http://www.elsevier.com/publishingethics and http://www.elsevier.com/ethicalguidelines.
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Policy and ethics
The work described in your article must have been carried out in accordance with The Code
of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving
humans http://www.wma.net/en/30publications/10policies/b3/index.html; EU Directive 2010/63/EU
for animal experiments http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm;
Uniform Requirements for manuscripts submitted to Biomedical journals http://www.icmje.org. This
must be stated at an appropriate point in the article.
Conflict of interest
All authors are requested to disclose any actual or potential conflict of interest including any financial,
personal or other relationships with other people or organizations within three years of beginning the
submitted work that could inappropriately influence, or be perceived to influence, their work. See
also http://www.elsevier.com/conflictsofinterest.
Submission declaration
Submission of an article implies that the work described has not been published previously (except
in the form of an abstract or as part of a published lecture or academic thesis), that it is not under
consideration for publication elsewhere, that its publication is approved by all authors and tacitly or
explicitly by the responsible authorities where the work was carried out, and that, if accepted, it
will not be published elsewhere including electronically in the same form, in English or in any other
language, without the written consent of the copyright-holder.
Changes to authorship
This policy concerns the addition, deletion, or rearrangement of author names in the authorship of
accepted manuscripts:
Before the accepted manuscript is published in an online issue: Requests to add or remove an author,
or to rearrange the author names, must be sent to the Journal Manager from the corresponding author
of the accepted manuscript and must include: (a) the reason the name should be added or removed,
or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that
they agree with the addition, removal or rearrangement. In the case of addition or removal of authors,
this includes confirmation from the author being added or removed. Requests that are not sent by
the corresponding author will be forwarded by the Journal Manager to the corresponding author, who
must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal
Editors of any such requests and (2) publication of the accepted manuscript in an online issue is
suspended until authorship has been agreed.
After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange
author names in an article published in an online issue will follow the same policies as noted above
and result in a corrigendum.
Clinical trial results
In line with the position of the International Committee of Medical Journal Editors, the journal will not
consider results posted in the same clinical trials registry in which primary registration resides to be
prior publication if the results posted are presented in the form of a brief structured (less than 500
words) abstract or table. However, divulging results in other circumstances (e.g., investors' meetings)
is discouraged and may jeopardise consideration of the manuscript. Authors should fully disclose all
posting in registries of results of the same or closely related work.
Reporting clinical trials
All randomised controlled trials submitted for publication should include a completed Consolidated
Standards of Reporting Trials (CONSORT) flow chart. Please refer to the CONSORT statement website
at http://www.consort-statement.org for more information. This journal has adopted the proposal
from the International Committee of Medical Journal Editors (ICMJE) which require, as a condition
of consideration for publication of clinical trials, registration in a public trials registry. Trials must
register at or before the onset of patient enrolment. The clinical trial registration number should be
included at the end of the abstract of the article. For this purpose, a clinical trial is defined as any
research study that prospectively assigns human participants or groups of humans to one or more
health-related interventions to evaluate the effects of health outcomes. Health-related interventions
include any intervention used to modify a biomedical or health-related outcome (for example drugs,
surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care
changes). Health outcomes include any biomedical or health-related measures obtained in patients or
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participants, including pharmacokinetic measures and adverse events. Purely observational studies
(those in which the assignment of the medical intervention is not at the discretion of the investigator)
will not require registration. Further information can be found at http://www.icmje.org.
Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for
more information on this and copyright see http://www.elsevier.com/copyright). Acceptance of the
agreement will ensure the widest possible dissemination of information. An e-mail will be sent to
the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing
Agreement' form or a link to the online version of this agreement.
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal
circulation within their institutions. Permission of the Publisher is required for resale or distribution
outside the institution and for all other derivative works, including compilations and translations
(please consult http://www.elsevier.com/permissions). If excerpts from other copyrighted works are
included, the author(s) must obtain written permission from the copyright owners and credit the
source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult
http://www.elsevier.com/permissions.
Retained author rights
As an author you (or your employer or institution) retain certain rights; for details you are referred
to: http://www.elsevier.com/authorsrights.
Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or
preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in
the collection, analysis and interpretation of data; in the writing of the report; and in the decision to
submit the article for publication. If the funding source(s) had no such involvement then this should
be stated. Please see http://www.elsevier.com/funding.
Funding body agreements and policies
Elsevier has established agreements and developed policies to allow authors whose articles appear in
journals published by Elsevier, to comply with potential manuscript archiving requirements as specified
as conditions of their grant awards. To learn more about existing agreements and policies please visit
http://www.elsevier.com/fundingbodies.
Language and language services
Please write your text in good English (American or British usage is accepted, but not a mixture of
these). Authors who require information about language editing and copyediting services pre- and
post-submission please visit http://webshop.elsevier.com/languageservices or our customer support
site at http://support.elsevier.com for more information.
Submission
Submission to this journal proceeds totally online and you will be guided stepwise through the creation
and uploading of your files. The system automatically converts source files to a single PDF file of the
article, which is used in the peer-review process. Please note that even though manuscript source
files are converted to PDF files at submission for the review process, these source files are needed for
further processing after acceptance. All correspondence, including notification of the Editor's decision
and requests for revision, takes place by e-mail removing the need for a paper trail.
Submit your article
Please submit your article via http://ees.elsevier.com/msard/
Referees
Please submit, with the manuscript, the names, addresses and e-mail addresses of three potential
referees. Note that the editor retains the sole right to decide whether or not the suggested reviewers
are used.
PREPARATION
Use of wordprocessing software
It is important that the file be saved in the native format of the wordprocessor used. The text should
be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes
will be removed and replaced on processing the article. In particular, do not use the wordprocessor's
options to justify text or to hyphenate words. However, do use bold face, italics, subscripts,
superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each
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individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns.
The electronic text should be prepared in a way very similar to that of conventional manuscripts
(see also the Guide to Publishing with Elsevier: http://www.elsevier.com/guidepublication). Note that
source files of figures, tables and text graphics will be required whether or not you embed your figures
in the text. See also the section on Electronic artwork.
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check'
functions of your wordprocessor.
Article structure
Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered
1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this
numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be
given a brief heading. Each heading should appear on its own separate line.
Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature
survey or a summary of the results.
Material and methods
Provide sufficient detail to allow the work to be reproduced. Methods already published should be
indicated by a reference: only relevant modifications should be described.
Results
Results should be clear and concise.
Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results
and Discussion section is often appropriate. Avoid extensive citations and discussion of published
literature.
Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand
alone or form a subsection of a Discussion or Results and Discussion section.
Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in
appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix,
Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.
Essential title page information
•  Title.  Concise and informative. Titles are often used in information-retrieval systems. Avoid
abbreviations and formulae where possible.
•  Author names and affiliations.  Where the family name may be ambiguous (e.g., a double
name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work
was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately
after the author's name and in front of the appropriate address. Provide the full postal address of
each affiliation, including the country name and, if available, the e-mail address of each author.
•  Corresponding author.  Clearly indicate who will handle correspondence at all stages of refereeing
and publication, also post-publication. Ensure that telephone and fax numbers (with country
and area code) are provided in addition to the e-mail address and the complete postal
address. Contact details must be kept up to date by the corresponding author.
•  Present/permanent address.  If an author has moved since the work described in the article
was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated
as a footnote to that author's name. The address at which the author actually did the work must be
retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
Abstract
A concise and factual abstract is required. The abstract should state briefly the purpose of the
research, the principal results and major conclusions. An abstract is often presented separately from
the article, so it must be able to stand alone. For this reason, References should be avoided, but if
essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should
be avoided, but if essential they must be defined at their first mention in the abstract itself.
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Graphical abstract
A Graphical abstract is optional and should summarize the contents of the article in a concise, pictorial
form designed to capture the attention of a wide readership online. Authors must provide images
that clearly represent the work described in the article. Graphical abstracts should be submitted as a
separate file in the online submission system. Image size: Please provide an image with a minimum
of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 ×
13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office
files. See http://www.elsevier.com/graphicalabstracts for examples.
Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best
presentation of their images also in accordance with all technical requirements: Illustration Service.
Highlights
Highlights are a short collection of bullet points that convey the core findings of the article. Highlights
are optional and should be submitted in a separate file in the online submission system. Please use
'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces,
per bullet point). See http://www.elsevier.com/highlights for examples.
Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and
avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing
with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords
will be used for indexing purposes.
Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page
of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first
mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.
Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do
not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those
individuals who provided help during the research (e.g., providing language help, writing assistance
or proof reading the article, etc.).
Math formulae
Present simple formulae in the line of normal text where possible and use the solidus (/) instead of
a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in
italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations
that have to be displayed separately from the text (if referred to explicitly in the text).
Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article, using
superscript Arabic numbers. Many wordprocessors build footnotes into the text, and this feature may
be used. Should this not be the case, indicate the position of footnotes in the text and present the
footnotes themselves separately at the end of the article. Do not include footnotes in the Reference
list.
Table footnotes
Indicate each footnote in a table with a superscript lowercase letter.
Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Save text in illustrations as 'graphics' or enclose the font.
• Only use the following fonts in your illustrations: Arial, Courier, Times, Symbol.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Produce images near to the desired size of the printed version.
• Submit each figure as a separate file.
A detailed guide on electronic artwork is available on our website:
http://www.elsevier.com/artworkinstructions
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You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
Regardless of the application used, when your electronic artwork is finalised, please 'save as' or
convert the images to one of the following formats (note the resolution requirements for line drawings,
halftones, and line/halftone combinations given below):
EPS: Vector drawings. Embed the font or save the text as 'graphics'.
TIFF: Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF: Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF: Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then
please supply 'as is'.
Please do not:
• Supply files that are optimised for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF, EPS or MS Office files) and with
the correct resolution. If, together with your accepted article, you submit usable color figures then
Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g.,
ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color
in the printed version. For color reproduction in print, you will receive information regarding
the costs from Elsevier after receipt of your accepted article. Please indicate your preference
for color: in print or on the Web only. For further information on the preparation of electronic artwork,
please see http://www.elsevier.com/artworkinstructions.
Please note: Because of technical complications which can arise by converting color figures to 'gray
scale' (for the printed version should you not opt for color in print) please submit in addition usable
black and white versions of all the color illustrations.
Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A
caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep
text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.
Tables
Number tables consecutively in accordance with their appearance in the text. Place footnotes to tables
below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be
sparing in the use of tables and ensure that the data presented in tables do not duplicate results
described elsewhere in the article.
References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice
versa). Any references cited in the abstract must be given in full. Unpublished results and personal
communications are not recommended in the reference list, but may be mentioned in the text. If these
references are included in the reference list they should follow the standard reference style of the
journal and should include a substitution of the publication date with either 'Unpublished results' or
'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted
for publication.
Reference management software
This journal has standard templates available in key reference management
packages EndNote http://www.endnote.com/support/enstyles.asp  and Reference Manager
http://refman.com/support/rmstyles.asp. Using plug-ins to wordprocessing packages, authors only
need to select the appropriate journal template when preparing their article and the list of references
and citations to these will be formatted according to the journal style which is described below.
Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any
further information, if known (DOI, author names, dates, reference to a source publication, etc.),
should also be given. Web references can be listed separately (e.g., after the reference list) under a
different heading if desired, or can be included in the reference list.
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References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in
the text) to other articles in the same Special Issue.
Reference style
Text: All citations in the text should refer to:
1. Single author: the author's name (without initials, unless there is ambiguity) and the year of
publication;
2. Two authors: both authors' names and the year of publication;
3. Three or more authors: first author's name followed by 'et al.' and the year of publication.
Citations may be made directly (or parenthetically). Groups of references should be listed first
alphabetically, then chronologically.
Examples: 'as demonstrated in wheat (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999). Kramer
et al. (2010) have recently shown ....'
List: References should be arranged first alphabetically and then further sorted chronologically if
necessary. More than one reference from the same author(s) in the same year must be identified by
the letters 'a', 'b', 'c', etc., placed after the year of publication.
Examples:
Reference to a journal publication:
Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun
2010;163:51–9.
Reference to a book:
Strunk Jr W, White EB. The elements of style. 4th ed. New York: Longman; 1979.
Reference to a chapter in an edited book:
Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ,
editors. Introduction to the electronic age. New York: E-Publishing Inc; 2009. p. 281–304.
Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6
should be listed followed by "et al." For further details you are referred to "Uniform Requirements
for Manuscripts submitted to Biomedical Journals" (J Am Med Assoc 1997;277:927–34) (see also
http://www.nlm.nih.gov/bsd/uniform_requirements.html).
Journal abbreviations source
Journal names should be abbreviated according to
Index Medicus journal abbreviations: http://www.nlm.nih.gov/tsd/serials/lji.html;
List of title word abbreviations: http://www.issn.org/2-22661-LTWA-online.php;
CAS (Chemical Abstracts Service): http://www.cas.org/sent.html.
Video data
Elsevier accepts video material and animation sequences to support and enhance your scientific
research. Authors who have video or animation files that they wish to submit with their article are
strongly encouraged to include these within the body of the article. This can be done in the same way
as a figure or table by referring to the video or animation content and noting in the body text where it
should be placed. All submitted files should be properly labeled so that they directly relate to the video
file's content. In order to ensure that your video or animation material is directly usable, please provide
the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and
animation files supplied will be published online in the electronic version of your article in Elsevier
Web products, including ScienceDirect: http://www.sciencedirect.com. Please supply 'stills' with your
files: you can choose any frame from the video or animation or make a separate image. These will
be used instead of standard icons and will personalize the link to your video data. For more detailed
instructions please visit our video instruction pages at http://www.elsevier.com/artworkinstructions.
Note: since video and animation cannot be embedded in the print version of the journal, please
provide text for both the electronic and the print version for the portions of the article that refer to
this content.
Supplementary data
Elsevier accepts electronic supplementary material to support and enhance your scientific research.
Supplementary files offer the author additional possibilities to publish supporting applications, high-
resolution images, background datasets, sound clips and more. Supplementary files supplied will be
published online alongside the electronic version of your article in Elsevier Web products, including
ScienceDirect: http://www.sciencedirect.com. In order to ensure that your submitted material is
directly usable, please provide the data in one of our recommended file formats. Authors should
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submit the material in electronic format together with the article and supply a concise and descriptive
caption for each file. For more detailed instructions please visit our artwork instruction pages at
http://www.elsevier.com/artworkinstructions.
Submission checklist
The following list will be useful during the final checking of an article prior to sending it to the journal
for review. Please consult this Guide for Authors for further details of any item.
Ensure that the following items are present:
One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
• Telephone and fax numbers
All necessary files have been uploaded, and contain:
• Keywords
• All figure captions
• All tables (including title, description, footnotes)
Further considerations
• Manuscript has been 'spell-checked' and 'grammar-checked'
• References are in the correct format for this journal
• All references mentioned in the Reference list are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Web)
• Color figures are clearly marked as being intended for color reproduction on the Web (free of charge)
and in print, or to be reproduced in color on the Web (free of charge) and in black-and-white in print
• If only color on the Web is required, black-and-white versions of the figures are also supplied for
printing purposes
For any further information please visit our customer support site at http://support.elsevier.com.
AFTER ACCEPTANCE
Use of the Digital Object Identifier
The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI
consists of a unique alpha-numeric character string which is assigned to a document by the publisher
upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal
medium for citing a document, particularly 'Articles in press' because they have not yet received their
full bibliographic information. The correct format for citing a DOI is shown as follows (example taken
from a document in the journal Physics Letters B):
doi:10.1016/j.physletb.2010.09.059
When you use the DOI to create URL hyperlinks to documents on the web, the DOIs are guaranteed
never to change.
Proofs
One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do
not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in
the e-mail so that authors can download the files themselves. Elsevier now provides authors with
PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 (or
higher) available free from http://get.adobe.com/reader. Instructions on how to annotate PDF files
will accompany the proofs (also given online). The exact system requirements are given at the Adobe
site: http://www.adobe.com/products/reader/tech-specs.html.
If you do not wish to use the PDF annotations function, you may list the corrections (including
replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections
quoting line number. If, for any reason, this is not possible, then mark the corrections and any other
comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan
the pages and e-mail, or by post. Please use this proof only for checking the typesetting, editing,
completeness and correctness of the text, tables and figures. Significant changes to the article as
accepted for publication will only be considered at this stage with permission from the Editor. We will
do everything possible to get your article published quickly and accurately – please let us have all your
corrections within 48 hours. It is important to ensure that all corrections are sent back to us in one
communication: please check carefully before replying, as inclusion of any subsequent corrections
cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with
the publication of your article if no response is received.
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Offprints
The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. For an
extra charge, paper offprints can be ordered via the offprint order form which is sent once the article
is accepted for publication. The PDF file is a watermarked version of the published article and includes
a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.
AUTHOR INQUIRIES
For inquiries relating to the submission of articles (including electronic submission) please
visit this journal's homepage. Contact details for questions arising after acceptance of
an article, especially those relating to proofs, will be provided by the publisher. You
can track accepted articles at http://www.elsevier.com/trackarticle. You can also check
our Author FAQs (http://www.elsevier.com/authorFAQ) and/or contact Customer Support via
http://support.elsevier.com.
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